TrialLineage Lineage

Phase 3 · Active

RNA-targeted therapy for Angelman syndrome

This lineage starts with a Phase 3 clinical trial of an antisense oligonucleotide for Angelman syndrome, then traces backward through the chain of science that made it possible: genomic imprinting, UBE3A biology, antisense chemistry, CNS delivery, and rare-disease trial design.

Start with the summaryLineage mapDiscovery timelineDeep-dive view

In plain language

The drug, the disease, and the chain of science behind both

Angelman syndrome is a rare genetic condition that causes severe developmental delays, movement and balance problems, seizures, and limited speech. It is caused by loss of function of one gene — UBE3A — in the brain. The paternal copy of UBE3A is intact but silenced by a natural antisense RNA.

ION582 (obudanersen) is an investigational antisense oligonucleotide designed to destroy the silencing RNA, potentially reactivating the intact paternal copy. If it works, neurons would regain a source of UBE3A protein.

But this trial did not appear out of nowhere. It exists because of a long chain of earlier scientific work — from the discovery of genomic imprinting to the identification of UBE3A, to decades of antisense chemistry, to the proof that intrathecal ASOs can reach the brain. This page traces that chain.

At a glance

  • The drug: ION582 (obudanersen), an antisense oligonucleotide delivered into the spinal fluid
  • The disease: Angelman syndrome — rare, severe neurodevelopmental disorder affecting ~1 in 15,000 people
  • The target: UBE3A-ATS, the antisense transcript that silences the paternal UBE3A gene in neurons
  • The trial: REVEAL (NCT06914609), Phase 3, testing whether UBE3A unsilencing improves developmental outcomes
  • Why it took decades: the silencing mechanism had to be discovered, ASO chemistry had to become practical medicine, and intrathecal CNS delivery had to be proven feasible

What had to happen first?

Six steps that made this trial possible

None of these steps alone produced a therapy. Each one built on the last, and the full chain took decades to assemble.

1

Name the syndrome

A pediatrician described a pattern of symptoms. Without clinical recognition, there was no defined disease to investigate.

2

Find the gene

Human geneticists identified UBE3A as the causative gene and discovered that neurons silence the paternal copy through imprinting.

3

Discover the silencing mechanism

Researchers found that UBE3A-ATS — a long antisense RNA — actively suppresses the paternal allele. A targetable molecule.

4

Invent the chemistry

Decades of work on antisense oligonucleotide design produced stable, potent molecules that could degrade specific RNA targets.

5

Prove CNS delivery

Nusinersen (Spinraza) for SMA proved that intrathecal ASOs could reach the brain and produce clinical benefit in humans.

6

Test in Angelman

ION582 entered clinical trials. Earlier phases assessed safety. The REVEAL Phase 3 trial now tests whether it works.

Reverse-lineage map

How this trial traces back through science

Read from top to bottom to see the chain of scientific fields that built on each other. Side branches show where the path diverged, where enabling methods were developed, and where prior work de-risked key steps.

Clinical trial

REVEAL Phase 3: ION582 in Angelman

▾

Clinical development

Earlier-phase safety studies

▾

Preclinical proof

ASO unsilencing in mouse models

▾

Therapeutic hypothesis

Destroy UBE3A-ATS → reactivate paternal UBE3A

▾

Mechanism discovery

UBE3A-ATS identified as silencing agent

▾

Disease genetics

UBE3A identified as causative gene

▾

Chromosomal mapping

15q11-q13 deletion and genomic imprinting

▾

Clinical recognition

Angelman syndrome described (1965)

Enabling method

Nusinersen / Spinraza (SMA)

Proved intrathecal ASOs could reach the CNS and produce clinical benefit.

Branch point

Prader-Willi vs. Angelman

Same chromosomal region, different parent. This proved imprinting.

Enabling method

Modified nucleotide chemistry

Decades of chemical refinement made ASOs practical drugs.

Open question

Timing of intervention

Can UBE3A restoration reverse established deficits?

Branch point

ASO vs. gene therapy vs. gene editing

Multiple modalities explored. ASO unsilencing is furthest advanced.

Enabling method

Angelman mouse models

Genetically engineered mice provided preclinical proof of concept.

Discovery timeline

Key moments in the path to this trial

Each step below made the next step possible. Without any one of them, this Phase 3 trial would not exist.

Milestone1950s–1960s

The central dogma and gene regulation

The discovery that genes encode proteins through RNA intermediates — and that RNA itself can regulate gene expression — provided the foundational biology that eventually made RNA-targeted therapy conceivable.

Milestone1965

A pediatrician names a syndrome

Harry Angelman described three children with severe intellectual disability, absent speech, movement difficulties, seizures, and an unusual behavioral profile. Without clinical recognition, there would have been no defined patient population to investigate.

Milestone1978

First antisense oligonucleotide experiment

Zamecnik and Stephenson demonstrated that a synthetic nucleotide strand complementary to an RNA sequence could block that RNA’s function. This proof of principle opened an entire class of potential therapeutics, though decades of chemistry would be needed to make them practical drugs.

MilestoneLate 1980s

Chromosomal mapping and the discovery of imprinting

Cytogenetic studies identified deletions on chromosome 15q11-q13 in Angelman patients. Only maternal deletions caused the syndrome, while paternal deletions caused Prader-Willi. This introduced the concept of genomic imprinting — genes behaving differently depending on which parent they were inherited from.

Branch pointLate 1980s

Prader-Willi vs. Angelman: same region, different disease

The finding that maternal and paternal deletions of the same chromosomal region caused entirely different diseases proved that parent-of-origin mattered. This was one of the first demonstrations of genomic imprinting in human disease and narrowed the molecular search.

Milestone1997

UBE3A identified as the causative gene

Multiple research groups demonstrated that mutations in UBE3A alone were sufficient to cause Angelman syndrome, and that in neurons, only the maternal copy is active. This established the molecular target: restore UBE3A protein in neurons.

Milestone1990s–2000s

Making antisense chemistry work as medicine

Researchers developed modified nucleotide backbones that resisted degradation, improved binding affinity, reduced toxicity, and could be manufactured at scale. Much of this chemistry was pioneered at Ionis Pharmaceuticals. It transformed a laboratory curiosity into a viable drug platform.

Milestone2005–2012

Discovery of the silencing mechanism

Researchers identified UBE3A-ATS — a long non-coding antisense RNA originating from the SNURF-SNRPN locus — as the molecule that suppresses paternal UBE3A in neurons. The paternal gene was intact but actively silenced by a targetable RNA. A therapeutic hypothesis emerged: destroy the silencing RNA.

Milestone2012–2015

Proof of concept in Angelman mouse models

ASOs targeting UBE3A-ATS partially restored paternal UBE3A protein expression in neurons and improved disease-related phenotypes in genetically engineered mice. First direct evidence that the therapeutic hypothesis could work in a living organism.

Convergence2016

Intrathecal ASOs proven feasible in humans

Nusinersen (Spinraza) for spinal muscular atrophy proved that antisense oligonucleotides could be delivered into the spinal fluid, reach the CNS, and produce clinical benefit in a neurodevelopmental disease. This validated the delivery route ION582 would use.

Milestone2020–2023

First human testing in Angelman syndrome

ION582 (obudanersen) entered clinical testing in children with Angelman syndrome. Earlier-phase studies assessed safety, tolerability, and biological activity following intrathecal administration.

Convergence2024–present

Phase 3: testing whether it works

The REVEAL trial (NCT06914609) evaluates whether ION582 produces clinically meaningful improvement in developmental outcomes. Six decades of accumulated knowledge — from the central dogma to imprinting to antisense chemistry to CNS delivery — converges into a single controlled experiment.

Why this lineage matters

This lineage illustrates how understanding a gene-regulation mechanism can lead to a therapeutic hypothesis in a rare genetic disease. The logic is specific: the paternal UBE3A allele is intact but silenced; the silencing mechanism is a readable antisense transcript; ASO technology can target that transcript; therefore ASO-mediated unsilencing is a rationally designed intervention.

Platform technology made it possible

ION582 exists because decades of prior work on antisense chemistry, CNS delivery, and manufacturing created a mature infrastructure. Nusinersen in SMA validated the intrathecal approach and de-risked the delivery route.

The question this trial answers

Whether a rational biological hypothesis — ASO-mediated unsilencing of paternal UBE3A — translates into clinical benefit for patients with Angelman syndrome. The scientific lineage is coherent; the clinical outcome is still unknown.

Deep-dive view

The longer scientific lineage

Each section below expands on one layer of the discovery chain.

1. Molecular biology had to understand RNA regulation

Before anyone could propose targeting a specific RNA transcript to treat a genetic disease, the field had to understand that genes encode proteins through RNA intermediates and that RNA can regulate gene expression. The central dogma — and its elaborations including non-coding RNAs — provided the conceptual framework.

2. A syndrome had to be named and a gene had to be found

Harry Angelman described the clinical pattern in 1965. Cytogenetic studies in the 1980s mapped the cause to chromosome 15q11-q13. In 1997, UBE3A was identified as the causative gene — subject to brain-specific maternal-only expression. This gave the field a molecular target.

3. The silencing mechanism had to be identified

The crucial discovery: paternal UBE3A in neurons is not deleted or mutated — it is actively suppressed by a long non-coding antisense RNA transcript (UBE3A-ATS). This meant the paternal gene was intact and potentially reactivatable. A drug that could destroy UBE3A-ATS might unsilence it. This was the pivotal therapeutic hypothesis.

4. Antisense chemistry had to become practical medicine

The original 1978 ASO experiment proved the principle. But making ASOs into drugs required decades of chemical engineering: modified backbones for stability, improved binding affinity, reduced toxicity, scalable manufacturing. This work — much of it at Ionis Pharmaceuticals — transformed a laboratory curiosity into a drug platform capable of producing clinical candidates.

5. CNS delivery had to be proven in humans

Even with the right chemistry and the right target, the drug had to reach neurons inside the central nervous system. The approval of nusinersen for SMA in 2016 proved that intrathecal ASO delivery worked: the drug reached motor neurons, produced clinical benefit, and was tolerable over chronic dosing. This de-risked the delivery route for ION582.

6. The full chain converges in REVEAL

The Phase 3 trial tests whether destroying UBE3A-ATS in children with Angelman syndrome produces clinically meaningful improvement. Every upstream discovery — from imprinting biology to antisense chemistry to CNS delivery validation — had to succeed before this experiment could be proposed.

Known vs. unknown

What the evidence says and what remains open

Established

  • Angelman syndrome is caused by loss of neuronal UBE3A expression
  • The paternal UBE3A allele is silenced in neurons by UBE3A-ATS
  • ASOs targeting UBE3A-ATS can restore paternal UBE3A expression in animal models
  • Intrathecal ASO delivery to the CNS is feasible (demonstrated with nusinersen)
  • ION582 has undergone earlier-phase clinical evaluation
  • A Phase 3 trial (REVEAL) is active

Not yet known

  • Whether ION582 produces clinically meaningful improvement in developmental outcomes
  • Whether restored UBE3A expression can reverse established neurodevelopmental deficits
  • The optimal timing of intervention (age at treatment initiation)
  • Long-term safety of chronic intrathecal ASO administration in children
  • Whether benefit varies by genotype (deletion vs. other mechanisms)
  • Whether partial UBE3A restoration translates to functional improvement

Related concept pages

Connected scientific fields

RNA biologyRead explainer →Gene expressionRead explainer →Antisense oligonucleotidesRead explainer →Angelman syndromeRead explainer →UBE3ARead explainer →Rare genetic diseaseRead explainer →CNS drug deliveryRead explainer →Rare disease trialsRead explainer →Translational medicineRead explainer →

Sources and confidence

Endpoint record

ClinicalTrials.gov — NCT06914609: REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome.

Confidence flag

High for endpoint facts (active Phase 3 trial record on ClinicalTrials.gov). High for reverse-lineage structure (UBE3A biology, imprinting mechanism, ASO chemistry, and nusinersen precedent are well-established in published literature).

Source links

  • ClinicalTrials.gov NCT06914609 — REVEAL Phase 3 trial record
  • Kishino et al., Nature Genetics 1997 — UBE3A identification
  • Meng et al., Human Molecular Genetics 2015 — UBE3A-ATS and paternal silencing
  • Finkel et al., NEJM 2017 — nusinersen for SMA (intrathecal ASO precedent)
View trial record →